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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. They are characterized by two cardinal features: ineffective hematopoiesis leading to marrow failure and a propensity to transform to acute myeloid leukemia (AML). While significant progress has been made in revealing cytogenetic and molecular changes in AML (1, 2) less is known about the molecular changes that can lead to MDS. A number of nonspecific recurrent mutations have been described in MDS including NRAS (3) , TP53 (4) , RUNX1 (5, 6) , and FMS (7, 8) , with the recent additions of TET2 (9, 10) and ASXL1 (11, 12) .
However, given the heterogeneity of the disease it is of major importance to better characterize MDS patients on the molecular level, and to evaluate the prognostic relevance of new mutations. While clinical scoring systems like the World Health Organization (WHO)
adapted Prognostic Scoring System (WPSS) and the International Prognostic Scoring System (IPSS) (13, 14) can help to stratify patients according to risk of death and leukemic progression, good molecular prognostic markers are still missing (15 
Cytogenetic analysis and mutation analysis of IDH1/2 and NPM1
Cytogenetic analysis was performed centrally by G-and R-banding analysis. Mutation analysis was performed as described previously. was amplified using polymerase chain reaction (PCR) with the following primers:
5`TGTGTTGAGATGGACGCCTATTTG and 5`TGCCACCAACGACCAAGTCA as previously described. (16) The following primers were used for amplification of the genomic region that spans around wildtype R140 and R172 of IDH2 (exon four) using polymerase chain reaction: 5`GGGGTTCAAATTCTGGTTGA and 5`CTAGGCGAGGAGCTCCAGT.
PCR fragments were directly sequenced, and were analyzed using the Sequencing Analysis 
Results

Mutation status of IDH1/2 in MDS patients
Among 193 patients with MDS, seven patients (3.6%) had a heterozygous mutation in IDH1 codon 132. Six patients showed conversion of CGT to TGT leading to an Arg132Cys substitution and one patient had CGT to CAT conversion leading to Arg132His substitution ( 
Mutation status of IDH1/2 in patients with AML following MDS
Among the 53 AML patients with a previous history of MDS, four patients (7.5%) had IDH1 mutations in codon 132. Two patients showed conversion of CGT to CAT, one patient had conversion of CGT to TGT, and one patient had conversion of CGT to AGT leading to an Arg132Ser substitution. Three out of 53 patients with AML from MDS were found to have mutations in codon R140 of IDH2. All showed a conversion of CGG to CAG leading to an arginine to glutamine substitution. One patient with AML from MDS had an IDH2 mutation in codon 172 causing a conversion of AGG to AGT that leads to an Arg172Ser substitution (Table 2) . Thus, 15 percent of AML patients with a history of MDS had mutated IDH1 or IDH2. Mutated NPM1 was found in 3 from 33 studied patients with AML from MDS; of those, one had also mutated IDH1.
Patient characteristics in relation to IDH1/2 mutations
The clinical and hematological characteristics of mutated versus unmutated patients are compared in Table 3 . There was no difference in age, sex, WHO-classification, karyotype, bone marrow blasts, hemoglobin, transfusion dependence, ferritin, IPSS score, or number of treatments between the IDH1 mutated versus wildtype groups.
Prognostic impact of IDH1 mutations
The prognostic impact of IDH1 mutations was evaluated in MDS patients for whom followup information was available (n=153). The median follow-up of patients alive was 3 years. In univariate analysis OS of patients with IDH1 mutation was significantly shorter compared to patients with wildtype IDH1 (HR 3.20; 95%CI 1.47-6.99; Figure 3A ). score, transfusion dependence, and karyotype, the presence of IDH1 mutations was found to be an independent unfavorable prognostic factor for EFS (Table 4) .
Discussion
In the present study we identify IDH1 mutations as a recurring molecular aberration in MDS patients with a frequency of 3.6%. Moreover, mutated IDH1 was associated with a high rate of leukemic transformation, and a poor event-free and overall survival. In this study, mutated IDH1 was an independent unfavorable prognostic marker for EFS and OS of MDS patients. Different treatment regimens did not influence prognosis in our cohort (data not shown), suggesting that treatment differences between these patients are less likely to have a confounding effect on our analysis. The present study provides a potential new Event-free survival in MDS patients (n=153) with mutated (n= 7) and unmutated (n=146)
IDH1 (log-rank test, P=0.02). Hazard ratios greater than 1 indicate an increased risk of an event for the first category listed.
HR, hazard ratio; CI, confidence interval. Suppl. Figure 1 Sample Description Suppl. Figure 1 . Description of patient samples. MDS: myelodysplastic syndrome; AML: acute myeloid leukemia.
